Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Operating Income (2016 - 2025)

BioCorRx's Operating Income history spans 15 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Operating Income fell 17.22% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$5.4 million, down 12.48%, while the annual FY2024 figure was -$5.1 million, 35.24% down from the prior year.
  • Operating Income for Q3 2025 was -$1.9 million at BioCorRx, down from -$1.4 million in the prior quarter.
  • Across five years, Operating Income topped out at -$822712.0 in Q4 2023 and bottomed at -$1.9 million in Q3 2025.
  • The 5-year median for Operating Income is -$1.1 million (2024), against an average of -$1.2 million.
  • The largest annual shift saw Operating Income soared 55.28% in 2021 before it plummeted 72.55% in 2024.
  • A 5-year view of Operating Income shows it stood at -$1.3 million in 2021, then rose by 11.03% to -$1.2 million in 2022, then surged by 30.62% to -$822712.0 in 2023, then tumbled by 36.71% to -$1.1 million in 2024, then tumbled by 72.98% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Operating Income are -$1.9 million (Q3 2025), -$1.4 million (Q2 2025), and -$937946.0 (Q1 2025).